Prognostic impact of tumor deposits on overall survival in colorectal cancer: Based on Surveillance, Epidemiology, and End Results database

doi:10.4251/wjgo.v14.i9.1699

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5415)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

229

WORD

HTML

2055

Figures (1-1)

466

Tables (1-5)

438

Sum=3267

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

512

Download

1636

Sum=2148

Sep 15, 2022 (publication date) through Nov 11, 2025

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Cohort Study

World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1699-1710
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1699

Table 1 Characteristics of patients according to the presence and absence of tumor deposits

	Tumor deposits		P value
	No (89624)	Yes (14131)	P value
Sex			0.827
Female	43569 (48.6%)	6855 (48.5%)
Male	46055 (51.4%)	7276 (51.5%)
Race			0.420
White	70019 (78.1%)	11015 (77.9%)
Black	10345 (11.5%)	1681 (11.9%)
Others	9260 (10.3%)	1435 (10.2%)
Age group, yr			< 0.001^a
< 45	5740 (6.40%)	1231 (8.71%)
45-75	58860 (65.7%)	9387 (66.4%)
≥ 75	25024 (27.9%)	3513 (24.9%)
TNM-stage			< 0.001^a
Ι	24816 (27.7%)	111 (0.79%)
ΙΙ	29374 (32.8%)	825 (5.84%)
ΙΙΙ	26627 (29.7%)	7697 (54.5%)
ΙV	8807 (9.83%)	5498 (38.9%)
T-stage			< 0.001^a
T1	15480 (17.3%)	181 (1.28%)
T2	14312 (16.0%)	482 (3.41%)
T3	47654 (53.2%)	7890 (55.8%)
T4	12178 (13.6%)	5578 (39.5%)
N-stage			< 0.001^a
N0	56512 (63.1%)	1247 (8.82%)
N1	22127 (24.7%)	6582 (46.6%)
N2	10985 (12.3%)	6302 (44.6%)
M-stage			< 0.001^a
M0	80817 (90.2%)	8633 (61.1%)
M1	8807 (9.83%)	5498 (38.9%)
Liver metastasis			< 0.001^a
No	82821 (92.4%)	10377 (73.4%)
Yes	6443 (7.19%)	3627 (25.7%)
Unknown	360 (0.40%)	127 (0.90%)
Lung metastasis			< 0.001^a
No	87677 (97.8%)	13053 (92.4%)
Yes	1526 (1.70%)	893 (6.32%)
Unknown	421 (0.47%)	185 (1.31%)
Site			< 0.001^a
Colon	71779 (80.1%)	11697 (82.8%)
Rectum	16603 (18.5%)	2148 (15.2%)
Unknown	1242 (1.39%)	286 (2.02%)
CEA			< 0.001^a
Normal	32166 (35.9%)	3543 (25.1%)
Elevated	20936 (23.4%)	5705 (40.4%)
Borderline	279 (0.31%)	48 (0.34%)
Unknown	36243 (40.4%)	4835 (34.2%)
Perineural invasion			< 0.001^a
Negative	75025 (83.7%)	8437 (59.7%)
Positive	7301 (8.15%)	4659 (33.0%)
Unknown	7298 (8.14%)	1035 (7.32%)

^aP < 0.05.

TNM: Tumor, node and metastasis; CEA: Carcinoembryonic antigen.

Full Size Table

Table 2 Overall survival univariate and multivariate Cox models of baseline characteristics

	Univariate Cox models			Multivariate Cox model
	Events/total	HR (95%CI)	P value	Events/total	HR (95%CI)	P value
Sex			0.3665
Female	19008/50424	Reference
Male	20358/53331	1.01 (0.99-1.03)	0.3665
Race			< 0.0001^a			< 0.0001^a
White	30958/81034	Reference		27279/73091	Reference
Black	5049/12026	1.14 (1.11-1.17)	< 0.0001^a	4440/10821	1.19 (1.16-1.23)	< 0.0001^a
Others	3359/10695	0.80(0.77-0.83)	<.0001^a	2926/9552	0.83(0.80-0.86)	<.0001^a
Age group, yr			< 0.0001^a			< 0.0001^a
< 45	1866/6971	Reference		1627/6276	Reference
45-75	20956/68247	1.17 (1.11-1.22)	< 0.0001^a	18394/61529	1.49 (1.42-1.57)	< 0.0001^a
≥ 75	16544/28537	2.78 (2.65-2.92)	< 0.0001^a	14624/25659	4.40 (4.17-4.63)	< 0.0001^a
TNM-stage			< 0.0001^a			< 0.0001^a
Ι	4709/24927	Reference		4154/22321	Reference
ΙΙ	9334/30199	1.79 (1.73-1.85)	< 0.0001^a	8362/27688	0.96 (0.89-1.02)	0.2060
ΙΙΙ	13498/34324	2.46 (2.38-2.55)	< 0.0001^a	12086/31183	1.32 (1.21-1.43)	< 0.0001^a
ΙV	11825/14305	9.08 (8.77-9.40)	< 0.0001^a	10043/12272	3.27 (2.99-3.56)	< 0.0001^a
T-stage			< 0.0001^a			< 0.0001^a
T1	2794/15661	Reference		2259/13476	Reference
T2	3477/14794	1.35 (1.29-1.42)	< 0.0001^a	3167/13728	1.18 (1.12-1.25)	< 0.0001^a
T3	21562/55544	2.52 (2.42-2.62)	< 0.0001^a	19171/50529	1.71 (1.59-1.83)	< 0.0001^a
T4	11533/17756	5.80 (5.57-6.05)	< 0.0001^a	10048/15731	2.83 (2.63-3.05)	< 0.0001^a
N-stage			< 0.0001^a			< 0.0001^a
N0	16014/57759	Reference		14081/52146	Reference
N1	12199/28709	1.73 (1.69-1.78)	< 0.0001^a	10718/25885	0.96 (0.91-1.02)	0.1880
N2	11153/17287	3.38 (3.30-3.47)	< 0.0001^a	9846/15433	1.44 (1.36-1.53)	< 0.0001^a
M-stage			< 0.0001^a
M0	27541/89450	Reference
M1	11825/14305	5.05 (4.94-5.16)	< 0.0001^a
Liver metastasis			< 0.0001^a			< 0.0001^a
No	30670/93198	Reference		27418/84728	Reference
Yes	8406/10070	4.67(4.56-4.79)	< 0.0001^a	7227/8736	1.33(1.28-1.39)	< 0.0001^a
Lung metastasis			< 0.0001^a			< 0.0001^a
No	36847/100730	Reference		32838/91390	Reference
Yes	2119/2419	4.62 (4.42-4.83)	< 0.0001^a	1807/2074	1.32 (1.25-1.38)	< 0.0001^a
Site			< 0.0001^a
Colon	32774/83476	Reference
Rectum	5782/18751	0.71 (0.69-0.73)	< 0.0001^a
CEA			< 0.0001^a
Normal	9708/35709	Reference
Elevated	14098/26641	2.46 (2.40-2.53)	< 0.0001^a
Borderline	125/327	1.51 (1.26-1.80)	0.0001^a
Perineural invasion			< 0.0001^a			< 0.0001^a
Negative	28478/83462	Reference		27655/81868	Reference
Positive	7260/11960	2.32 (2.26-2.38)	< 0.0001^a	6990/11596	1.22 (1.19-1.26)	< 0.0001^a
Tumor deposits			< 0.0001^a			< 0.0001^a
No	30165/89624	Reference		26523/80813	Reference
Yes	9201/14131	2.73 (2.67-2.80)	< 0.0001^a	8122/12651	1.35 (1.31-1.38)	< 0.0001^a

^aP < 0.05.

TNM: Tumor, node and metastasis; CEA: Carcinoembryonic antigen.

Full Size Table

Table 3 Sensitivity analysis for effect of tumor deposits on overall survival

Analysis	HR (95%CI)	P value
Univariable analysis	2.73 (2.67-2.80)	< 0.0001^a
Multivariable analysis	1.35 (1.31-1.38)	< 0.0001^a
Propensity score analysis (with inverse probability of treatment weighting)	1.29 (1.19-1.39)	< 0.0001^a
Multiple imputation for missing data analysis	1.39 (1.35-1.42)	< 0.0001^a

^aP < 0.05.

HR: Hazard ratio.

Full Size Table

Table 4 Univariable Cox analysis in patients with and without tumor deposits

	TDs (no)			TDs (yes)			RHR	P value
	Events/total	HR (95%CI)	P value	Events/total	HR (95%CI)	P value	RHR	P value
Sex			0.1265			0.0528
Female	14534/43569	Reference		4474/6855	Reference
Male	15631/46055	1.02 (1.00-1.04)	0.1265	4727/7276	0.96 (0.92-1.00)	0.0528
Race			< 0.0001^a			< 0.0001
White	23736/70019	Reference		7222/11015	Reference
Black	3904/10345	1.16 (1.12-1.20)	< 0.0001^a	1145/1681	1.06 (1.00-1.13)	0.0536	0.91 (0.85-0.98)	0.0118^a
Others	2525/9260	0.79 (0.76-0.82)	< 0.0001^a	834/1435	0.83 (0.77-0.89)	< 0.0001^a	1.05 (0.97-1.14)	0.2380
Age group, yr			< 0.0001^a			< 0.0001^a
< 45	1201/5740	Reference		665/1231	Reference
45-75	15238/58860	1.26 (1.19-1.34)	< 0.0001^a	5718/9387	1.23 (1.13-1.33)	< 0.0001^a	0.98 (0.88-1.08)	0.6384
≥ 75	13726/25024	3.37 (3.18-3.58)	< 0.0001^a	2818/3513	2.34 (2.15-2.55)	< 0.0001^a	0.69 (0.63-0.77)	< 0.0001^a
TNM-stage			< 0.0001^a			< 0.0001^a
Ι	4683/24816	Reference		26/111	Reference
ΙΙ	8962/29374	1.77 (1.70-1.83)	< 0.0001^a	372/825	2.40 (1.61-3.57)	< 0.0001^a	1.36 (0.91-2.02)	0.1362
ΙΙΙ	9545/26627	2.17 (2.09-2.24)	< 0.0001^a	3953/7697	3.05 (2.08-4.49)	< 0.0001^a	1.41 (0.96-2.07)	0.0836
ΙV	6975/8807	8.05 (7.76-8.36)	< 0.0001^a	4850/5498	9.25 (6.29-13.6)	< 0.0001^a	1.15 (0.78-1.69)	0.4840
T-stage			< 0.0001^a			< 0.0001^a
T1	2726/15480	Reference		68/181	Reference
T2	3321/14312	1.35 (1.29-1.42)	< 0.0001^a	156/482	0.84 (0.63-1.11)	0.2246	0.62 (0.47-0.83)	0.0012^a
T3	17029/47654	2.30 (2.20-2.39)	< 0.0001^a	4533/7890	1.84 (1.45-2.34)	< 0.0001^a	0.80 (0.63-1.02)	0.0602
T4	7089/12178	4.84 (4.63-5.05)	< 0.0001^a	4444/5578	3.69 (2.90-4.68)	< 0.0001^a	0.76 (0.60-0.97)	0.0286^a
N-stage			< 0.0001^a			< 0.0001^a
N0	15350/56512	Reference		664/1247	Reference
N1	8434/22127	1.53 (1.49-1.57)	< 0.0001^a	3765/6582	1.14 (1.05-1.24)	0.0014^a	0.75 (0.68-0.81)	< 0.0001^a
N2	6381/10985	2.86 (2.77-2.94)	< 0.0001^a	4772/6302	1.99 (1.83-2.16)	< 0.0001^a	0.70 (0.64-0.76)	< 0.0001^a
M-stage			< 0.0001^a			< 0.0001^a
M0	23190/80817	Reference		4351/8633	Reference
M1	6975/8807	4.90 (4.77-5.04)	< 0.0001^a	4850/5498	3.13 (3.00-3.27)	< 0.0001^a	0.64 (0.61-0.67)	< 0.0001^a
Site			< 0.0001^a			< 0.0001^a
Colon	24983/71779	Reference		7791/11679	Reference
Rectum	4595/16603	0.74 (0.71-0.76)	< 0.0001^a	1187/2148	0.66 (0.62-0.71)	< 0.0001^a	0.89 (0.83-0.96)	0.0030^a
CEA			< 0.0001^a			< 0.0001^a
Normal	7926/32166	Reference		1782/3543	Reference
Elevated	9908/20936	2.34 (2.27-2.41)	< 0.0001^a	4190/5705	1.95 (1.84-2.06)	< 0.0001^a	0.83 (0.78-0.89)	< 0.0001^a
Borderline	95/279	1.47 (1.20-1.80)	0.0002^a	30/48	1.32 (0.92-1.89)	0.1343	0.90 (0.59-1.36)	0.6100
Perineural invasion			< 0.0001^a			< 0.0001^a
Negative	23417/75025	Reference		5061/8437	Reference
Positive	3845/7301	2.05 (1.98-2.12)	< 0.0001^a	3415/4659	1.46 (1.40-1.52)	< 0.0001^a	0.71 (0.68-0.75)	< 0.0001^a
Liver metastasis			< 0.0001^a			< 0.0001^a
No	24811/82821	Reference		5859/10377	Reference
Yes	5164/6443	4.73 (4.59-4.88)	< 0.0001^a	3242/3627	2.66 (2.54-2.78)	< 0.0001^a	0.56 (0.53-0.59)	< 0.0001^a
Lung metastasis			< 0.0001^a			< 0.0001^a
No	28622/87677	Reference		8225/13053	Reference
Yes	1297/1526	4.97 (4.70-5.25)	< 0.0001^a	822/893	2.40 (2.23-2.58)	< 0.0001^a	0.48 (0.44-0.53)	< 0.0001^a

^aP < 0.05.

TNM: Tumor, node and metastasis; CEA: Carcinoembryonic antigen; HR: Hazard ratio; TDs: Tumor deposits.

Full Size Table

Table 5 N1 colorectal cancers after being restaged

Initial N stage	Restaged N1	Restaged N2	Total
N1a/b	18077	752	18820
N1c	1003	133	1136
Total	19080	885	19965

Full Size Table

Citation: Wu WX, Zhang DK, Chen SX, Hou ZY, Sun BL, Yao L, Jie JZ. Prognostic impact of tumor deposits on overall survival in colorectal cancer: Based on Surveillance, Epidemiology, and End Results database. World J Gastrointest Oncol 2022; 14(9): 1699-1710
URL: https://www.wjgnet.com/1948-5204/full/v14/i9/1699.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i9.1699